Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
5.70
+0.01 (0.18%)
At close: Apr 2, 2026, 4:00 PM EDT
5.59
-0.11 (-1.93%)
After-hours: Apr 2, 2026, 7:01 PM EDT
Intensity Therapeutics Employees
As of December 31, 2024, Intensity Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,658,000
Market Cap
14.48M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 7 | 0 | - | 5 | 2 |
| Dec 31, 2023 | 7 | 3 | 75.00% | 5 | 2 |
| Mar 31, 2023 | 4 | -2 | -33.33% | 3 | 1 |
| Jun 30, 2022 | 4 | - | - | 4 | 0 |
| Mar 31, 2022 | 6 | - | - | 5 | 1 |
| Dec 31, 2021 | 6 | - | - | 5 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| Lantern Pharma | 24 |
| BioCardia | 20 |
| SeaStar Medical Holding | 19 |
| IN8bio | 17 |
| Genenta Science | 13 |
| Cocrystal Pharma | 11 |
| Traws Pharma | 7 |
INTS News
- 6 days ago - Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update - PRNewsWire
- 9 days ago - Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US - PRNewsWire
- 21 days ago - Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause - Benzinga
- 21 days ago - Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study - PRNewsWire
- 27 days ago - Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement - PRNewsWire
- 6 weeks ago - Intensity Therapeutics Announces Reverse Stock Split - PRNewsWire
- 2 months ago - Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities - PRNewsWire
- 4 months ago - Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium - PRNewsWire